Kalvista Pharmaceuticals Inc(KALV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KALV Kalvista Pharmaceuticals Inc

盘后交易 05-27 17:47:20 EDT

26.79

-0.02

-0.07%

盘后26.79

+0.000.00%

16:57 EDT

最高26.83	最低26.77	成交量246.67万
今开26.78	昨收26.81	日振幅0.22%
总市值14.24亿	流通市值11.88亿	总股本5,317万
成交额6,608万	换手率5.56%	流通股本4,435万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KALV","market":"US","secType":"STK","nameCN":"Kalvista Pharmaceuticals Inc","latestPrice":26.79,"timestamp":1779912000000,"preClose":26.81,"halted":0,"volume":2466702,"hourTrading":{"tag":"盘后","latestPrice":26.79,"preClose":26.79,"latestTime":"16:57 EDT","volume":14925,"amount":399875.719275,"timestamp":1779915437275,"change":0,"changeRate":0,"amplitude":0.000747},"delay":0,"changeRate":-0.0007459903021260565,"floatShares":44352999,"shares":53168000,"eps":-1.48,"marketStatus":"盘后交易","change":-0.02,"latestTime":"05-27 17:47:20 EDT","open":26.7799,"high":26.83,"low":26.77,"amount":66077986.042278,"amplitude":0.002238,"askPrice":26.85,"askSize":400,"bidPrice":26.77,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.48,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1779926400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1479790800000,"exchange":"NASDAQ","adjPreClose":26.81,"preHourTrading":{"tag":"盘前","latestPrice":26.78,"preClose":26.81,"latestTime":"09:29 EDT","volume":85875,"amount":2299394.4960000003,"timestamp":1779888599999,"change":-0.03,"changeRate":-0.001119,"amplitude":0.048862},"postHourTrading":{"tag":"盘后","latestPrice":26.79,"preClose":26.79,"latestTime":"16:57 EDT","volume":14925,"amount":399875.719275,"timestamp":1779915437275,"change":0,"changeRate":0,"amplitude":0.000747},"volumeRatio":0.495898,"impliedVol":0.5628,"impliedVolPercentile":0.3068},"requestUrl":"/m/hq/s/KALV/wiki","defaultTab":"wiki","newsList":[{"id":"1158048907","title":"Kalvista Pharmaceuticals Inc：Leerink Partners下调评级至“与大盘持平”，目标价上调至27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158048907","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158048907?lang=zh_cn&edition=full","pubTime":"2026-04-30 13:57","pubTimestamp":1777528628,"startTime":"0","endTime":"0","summary":"投资机构Leerink Partners宣布，将生物制药公司Kalvista Pharmaceuticals Inc的股票评级从“跑赢大盘”下调至“与大盘持平”。与此同时，该机构将其目标股价从原先的22美元显著上调至27美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155588647","title":"Chiesi集团达成协议 以每股27美元现金收购Kalvista制药公司 股权对价约19亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155588647","media":"美股速递","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155588647?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:45","pubTimestamp":1777463144,"startTime":"0","endTime":"0","summary":"意大利制药巨头Chiesi集团宣布已与Kalvista Pharmaceuticals Inc达成最终收购协议。根据协议条款，Chiesi将以每股27.00美元的现金价格收购这家专注于罕见病治疗的生物制药公司。此次交易对Kalvista制药公司的股权估值达到约19亿美元。该收购价格较Kalvista近期股价呈现显著溢价，体现了Chiesi集团对Kalvista在研产品管线价值的认可。交易完成后，Kalvista将成为Chiesi集团全球业务体系的重要组成部分。此项收购尚需获得监管机构批准及满足其他惯例成交条件。双方预计交易将于2024年下半年完成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166687342","title":"Kalvista制药公司：Sebetralstat耐受性良好，未出现严重或治疗相关不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1166687342","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166687342?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:02","pubTimestamp":1774868529,"startTime":"0","endTime":"0","summary":"Kalvista制药公司宣布，其研发药物Sebetralstat在临床试验中展现出良好的耐受性。研究数据显示，该药物未引发任何严重不良事件或与治疗相关的不良反应，为后续开发提供了积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135495251","title":"Kalvista制药公司计划于2026年第三季度提交Sebetralstat的美国新药申请，预计2027年上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1135495251","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135495251?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:01","pubTimestamp":1774868479,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals Inc宣布，其针对遗传性血管性水肿（HAE）的口服疗法Sebetralstat，计划于2026年第三季度向美国食品药品监督管理局（FDA）提交新药申请（NDA）。若审批顺利，该药物预计将在2027年正式上市。\n这一时间表的确定，标志着公司在推进该创新疗法商业化进程中迈出了关键一步。Sebetralstat作为一种便捷的口服药物，有望为HAE患者提供新的治疗选择，市场前景备受关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119578709","title":"Kalvista制药公布Ekterly®（Sebetralstat）用于2-11岁儿童Konfident-Kid试验积极3期中期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1119578709","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119578709?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:01","pubTimestamp":1774868476,"startTime":"0","endTime":"0","summary":"在2026年全球血管性水肿领导力会议上，Kalvista Pharmaceuticals Inc（简称：Kalvista）公布了其候选药物Ekterly®（Sebetralstat）针对2至11岁儿童开展的Konfident-Kid试验的积极3期中期数据。该数据进一步验证了该口服药物的有效性与安全性，为儿科遗传性血管性水肿治疗带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116211884","title":"Kalvista Pharmaceuticals Inc 中期数据显示：Sebetralstat可实现儿童遗传性血管性水肿的早期有效治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1116211884","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116211884?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:01","pubTimestamp":1774868475,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals Inc 最新公布的中期临床研究数据显示，其研究性药物Sebetralstat在儿童遗传性血管性水肿（HAE）患者中展现出良好的早期治疗效果。该数据表明，Sebetralstat能够使患者在症状出现早期即获得有效干预，从而可能改变儿童HAE的治疗模式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109462753","title":"Kalvista制药公司公布截至2025年12月31日八个月期间实现4910万美元净产品收入","url":"https://stock-news.laohu8.com/highlight/detail?id=1109462753","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109462753?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:11","pubTimestamp":1774437072,"startTime":"0","endTime":"0","summary":"Kalvista制药公司宣布，在截至2025年12月31日的八个月报告期内，公司确认了4910万美元的净产品收入。这一财务业绩凸显了公司核心产品的市场商业化进展与收入生成能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174235350","title":"Kalvista Pharmaceuticals公布2025财年八个月财务业绩并更新公司进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1174235350","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174235350?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:02","pubTimestamp":1774436525,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals Inc公布了截至2025财年八个月的财务业绩，同时提供了公司最新动态的全面更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130563625","title":"Kalvista Pharmaceuticals将于2026年3月25日发布八个月财年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1130563625","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130563625?lang=zh_cn&edition=full","pubTime":"2026-03-18 19:01","pubTimestamp":1773831677,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals Inc  宣布，将于2026年3月25日发布其2025财年前八个月的财务业绩，并同时提供公司业务进展的最新情况。Kalvista目前处于关键临床阶段，其现金储备与研发支出比例将直接影响投资者对其研发可持续性的判断。财报发布后，管理层将于美东时间当日上午8:30举行电话会议，届时预计将详细解读临床试验进展、与监管机构沟通情况以及未来十二个月的研发战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617470265","title":"Kalvista Pharmaceuticals, Inc.盘中异动 快速上涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617470265","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617470265?lang=zh_cn&edition=full","pubTime":"2026-03-04 23:37","pubTimestamp":1772638656,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日23时37分，Kalvista Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.06%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.65%。其相关个股中，Can Fite Biopharma Ltd、Moolec Science Sa C/Wts 30/01/2028、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Can Fite Biopharma Ltd、Klotho Neurosciences, Inc.、Onconetix, Inc.较为活跃，换手率分别为2160.20%、58.17%、48.98%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Klotho Neurosciences, Inc.、Can Fite Biopharma Ltd，振幅分别为114.71%、51.24%、41.60%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家制药公司，为未满足需求的患有罕见疾病的患者开发并提供口服疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304233737a6a2c08b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304233737a6a2c08b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0106261612.USD","HAE","IE00B19Z6F94.USD","LU0205193047.USD","LU0205194284.USD","LU1169589451.USD","IE0034390439.USD","BK4139","BK4198","LU0012050646.USD","IE00B64QTZ34.USD","LU1169590202.USD","IE00BLDYK493.USD","KALV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155661859","title":"Kalvista制药公司推进Konfident-Kid试验，计划于2026年第三季度为2至11岁患者提交Sebetralstat新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1155661859","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155661859?lang=zh_cn&edition=full","pubTime":"2026-02-18 20:03","pubTimestamp":1771416238,"startTime":"0","endTime":"0","summary":"Kalvista制药公司宣布，其针对2至11岁遗传性血管性水肿患儿的Konfident-Kid临床试验取得积极进展。公司计划于2026年第三季度向监管机构提交口服药物Sebetralstat的新药申请。该试验旨在评估Sebetralstat在儿科患者群体中的安全性和有效性，若获批将成为该年龄段首款口服预防药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179187958","title":"Kalvista Pharmaceuticals宣布Ekterly®（Sebetralstat）被纳入国际儿科HAE指南，成为12岁及以上青少年一线疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1179187958","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179187958?lang=zh_cn&edition=full","pubTime":"2026-02-18 20:03","pubTimestamp":1771416207,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals Inc近日宣布，其研发的药物Ekterly已被正式列入国际儿科遗传性血管性水肿治疗指南，作为12岁及以上青少年患者的一线治疗方案。这一重要进展标志着Ekterly在青少年HAE治疗领域的临床价值获得国际权威认可。作为一款口服靶向药物，Ekterly凭借其快速起效和良好的安全性特征，为青少年患者提供了一种便捷、高效的治疗选择。此次纳入指南将进一步巩固Kalvista在罕见病治疗领域的创新地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603653069","title":"Kalvista Pharmaceuticals, Inc.盘中异动 股价大跌5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603653069","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603653069?lang=zh_cn&edition=full","pubTime":"2026-01-14 00:29","pubTimestamp":1768321774,"startTime":"0","endTime":"0","summary":"北京时间2026年01月14日00时29分，Kalvista Pharmaceuticals, Inc.股票出现异动，股价快速跳水5.25%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.30%。其相关个股中，Xtl生物制药、Decoy Therapeutics Inc.、Briacell Therapeutics Corp.涨幅较大，Decoy Therapeutics Inc.、Scisparc Ltd.、Briacell Therapeutics Corp.较为活跃，换手率分别为1393.28%、1174.36%、334.36%，振幅较大的相关个股有Xtl生物制药、Lexaria Bioscience Corp C/Wts 14/01/2026 、Decoy Therapeutics Inc.，振幅分别为96.62%、67.92%、41.72%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家制药公司，为未满足需求的患有罕见疾病的患者开发并提供口服疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114002935953ca0c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114002935953ca0c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0034390439.USD","IE00B19Z6F94.USD","LU0106261612.USD","HAE","KALV","IE00BLDYK493.USD","LU1169589451.USD","LU0205194284.USD","BK4139","BK4198","LU0205193047.USD","LU0012050646.USD","IE00B64QTZ34.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603892046","title":"Kalvista Pharmaceuticals, Inc.盘中异动 早盘快速下跌5.00%报15.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603892046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603892046?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:46","pubTimestamp":1768229172,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时46分，Kalvista Pharmaceuticals, Inc.股票出现异动，股价大幅下跌5.00%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.06%。其相关个股中，Cdt Equity Inc C/Wts 22/09/2028、Day One Biopharmaceuticals, Inc.、Forte Biosciences, Inc.涨幅较大，Jaguar Health, Inc.、Osr Holdings, Inc.、Genprex, Inc.较为活跃，换手率分别为539.57%、112.53%、53.83%，振幅较大的相关个股有Pyxis Oncology, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Geovax Labs, Inc.，振幅分别为26.42%、25.56%、24.64%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家制药公司，为未满足需求的患有罕见疾病的患者开发并提供口服疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112224613a7120f54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112224613a7120f54&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0106261612.USD","IE00B64QTZ34.USD","IE00BLDYK493.USD","LU0205193047.USD","KALV","LU0205194284.USD","LU1169590202.USD","BK4198","IE00B19Z6F94.USD","BK4139","LU0012050646.USD","LU1169589451.USD","HAE","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178822520","title":"Kalvista制药公布Ekterly®强劲上市进展及2025年第四季度与全年初步营收业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1178822520","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178822520?lang=zh_cn&edition=full","pubTime":"2026-01-09 05:06","pubTimestamp":1767906375,"startTime":"0","endTime":"0","summary":"Kalvista制药公司近日发布了其创新药物Ekterly®上市后的积极动态，同时披露了2025财年第四季度及全年的初步营收数据。初步结果显示，Ekterly®的市场推广势头强劲，为公司全年营收做出了显著贡献。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KALV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149381360","title":"Kalvista Pharmaceuticals在日本获得Ekterly® (Sebetralstat)的批准，成为首个也是唯一的口服按需治疗遗传性水肿的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1149381360","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149381360?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:01","pubTimestamp":1766401271,"startTime":"0","endTime":"0","summary":"Kalvista Pharmaceuticals在日本获得Ekterly® (Sebetralstat)的批准，成为首个也是唯一的口服按需治疗遗传性水肿的药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517985069","title":"Kalvista Pharmaceuticals, Inc.盘中异动 大幅拉升5.11%报11.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517985069","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517985069?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:27","pubTimestamp":1741120066,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时27分，Kalvista Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.11%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Rapport Therapeutics, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Aeon Biopharma, Inc.、Protagenic Therapeutics, Inc.、Windtree Therapeutics, Inc.较为活跃，换手率分别为1330.19%、1258.60%、1224.41%，振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Plus Therapeutics, Inc.，振幅分别为122.48%、68.89%、68.09%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030504274696399744&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030504274696399744&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KALV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516637427","title":"Citizens Capital Markets：重申KalVista Pharma(KALV.US)评级，由优于大市调整至优于大市评级, 目标价由19.00美元调整至19.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637427","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516637427?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:11","pubTimestamp":1741014689,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets：重申KalVista Pharma(KALV.US)评级，由优于大市调整至优于大市评级, 目标价由19.00美元调整至19.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03231148494584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KALV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516148371","title":"Kalvista Pharmaceuticals, Inc.盘中异动 急速拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516148371","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516148371?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:36","pubTimestamp":1740760606,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时36分，Kalvista Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.08%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Bioxcel Therapeutics, Inc.、Camp4 Therapeutics Corporation、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为2922.48%、491.11%、364.17%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为57.80%、46.60%、43.95%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010036479634359a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010036479634359a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KALV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514542788","title":"Kalvista Pharmaceuticals, Inc.盘中异动 大幅上涨5.06%报11.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514542788","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514542788?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:38","pubTimestamp":1740584333,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时38分，Kalvista Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.06%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Humacyte Inc C/Wts 27/08/2026 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为5229.01%、197.73%、185.00%，振幅较大的相关个股有Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Humacyte Inc C/Wts 27/08/2026 ，振幅分别为161.02%、43.31%、39.47%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家专注于发现、开发和商业化用于一系列疾病的小分子蛋白酶抑制剂的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262338539893b7af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262338539893b7af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KALV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kalvista.com","stockEarnings":[{"period":"1week","weight":0.0015},{"period":"1month","weight":0.3658},{"period":"3month","weight":0.7011},{"period":"6month","weight":0.9014},{"period":"1year","weight":1.3374},{"period":"ytd","weight":0.6601}],"compareEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":0.0513},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1043},{"period":"1year","weight":0.2961},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"KalVista Pharmaceuticals, Inc.于2004年3月26日在特拉华州注册成立。该公司是一家临床阶段制药公司，专注于发现、开发和商业化小分子蛋白酶抑制剂，用于有重大未满足需求的疾病。该公司运用他们对蛋白酶的化学和生物学的洞见，开发出具有高选择性、效力和生物利用度的口服疗法，该公司相信这将使它们成为治疗疾病的成功药物。该公司利用这些能力开发了针对遗传性血管性水肿（HAE）的新型小分子血浆激肽释放酶抑制剂。该公司还在进行一项新的口服XIIa因子（“XIIa因子”）抑制剂项目的临床前开发。该公司正在初步推进这一项目，以提供下一代HAE疗法，这也为将来扩展到其他未满足的高需求适应症提供了机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.01082},{"month":2,"riseRate":0.6,"avgChangeRate":0.167299},{"month":3,"riseRate":0.5,"avgChangeRate":-0.03011},{"month":4,"riseRate":0.5,"avgChangeRate":0.059889},{"month":5,"riseRate":0.5,"avgChangeRate":-0.035812},{"month":6,"riseRate":0.555556,"avgChangeRate":-0.005524},{"month":7,"riseRate":0.555556,"avgChangeRate":0.039581},{"month":8,"riseRate":0.555556,"avgChangeRate":0.149368},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.065906},{"month":10,"riseRate":0.333333,"avgChangeRate":0.007901},{"month":11,"riseRate":0.555556,"avgChangeRate":0.074914},{"month":12,"riseRate":0.5,"avgChangeRate":0.048897}],"exchange":"NASDAQ","name":"Kalvista Pharmaceuticals Inc","nameEN":"Kalvista Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kalvista Pharmaceuticals Inc(KALV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kalvista Pharmaceuticals Inc(KALV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kalvista Pharmaceuticals Inc,KALV,Kalvista Pharmaceuticals Inc股票,Kalvista Pharmaceuticals Inc股票老虎,Kalvista Pharmaceuticals Inc股票老虎国际,Kalvista Pharmaceuticals Inc行情,Kalvista Pharmaceuticals Inc股票行情,Kalvista Pharmaceuticals Inc股价,Kalvista Pharmaceuticals Inc股市,Kalvista Pharmaceuticals Inc股票价格,Kalvista Pharmaceuticals Inc股票交易,Kalvista Pharmaceuticals Inc股票购买,Kalvista Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kalvista Pharmaceuticals Inc(KALV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kalvista Pharmaceuticals Inc(KALV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}